126 related articles for article (PubMed ID: 38341081)
1. Inhibition of RhoGEF/RhoA alleviates regorafenib resistance and cancer stemness via Hippo signaling pathway in hepatocellular carcinoma.
Zhou HM; Chen DH; Diao WJ; Wu YF; Zhang JG; Zhong L; Jiang ZY; Zhang X; Liu GL; Li Q
Exp Cell Res; 2024 Mar; 436(1):113956. PubMed ID: 38341081
[TBL] [Abstract][Full Text] [Related]
2. RAB27A-dependent release of exosomes by liver cancer stem cells induces Nanog expression in their differentiated progenies and confers regorafenib resistance.
Huang H; Hou J; Liu K; Liu Q; Shen L; Liu B; Lu Q; Zhang N; Che L; Li J; Jiang S; Wang B; Wen Q; Hu L; Gao J
J Gastroenterol Hepatol; 2021 Dec; 36(12):3429-3437. PubMed ID: 34258777
[TBL] [Abstract][Full Text] [Related]
3. FOXM1-CD44 Signaling Is Critical for the Acquisition of Regorafenib Resistance in Human Liver Cancer Cells.
Wuputra K; Hsiao PJ; Chang WT; Wu PH; Chen LA; Huang JW; Su WL; Yang YH; Wu DC; Yokoyama KK; Kuo KK
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887129
[TBL] [Abstract][Full Text] [Related]
4. Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway.
Wang J; Zhang N; Han Q; Lu W; Wang L; Yang D; Zheng M; Zhang Z; Liu H; Lee TH; Zhou XZ; Lu KP
Cancer Lett; 2019 Mar; 444():82-93. PubMed ID: 30583078
[TBL] [Abstract][Full Text] [Related]
5. Antitumor Effect of Regorafenib on MicroRNA Expression in Hepatocellular Carcinoma Cell Lines.
Takuma K; Fujihara S; Fujita K; Iwama H; Nakahara M; Oura K; Tadokoro T; Mimura S; Tani J; Shi T; Morishita A; Kobara H; Himoto T; Masaki T
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163589
[TBL] [Abstract][Full Text] [Related]
6. Suppression of LSD1 enhances the cytotoxic and apoptotic effects of regorafenib in hepatocellular carcinoma cells.
Wu LW; Zhou DM; Zhang ZY; Zhang JK; Zhu HJ; Lin NM; Zhang C
Biochem Biophys Res Commun; 2019 May; 512(4):852-858. PubMed ID: 30929918
[TBL] [Abstract][Full Text] [Related]
7. Induction of IL-6Rα by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma.
Dai Z; Wang X; Peng R; Zhang B; Han Q; Lin J; Wang J; Lin J; Jiang M; Liu H; Lee TH; Lu KP; Zheng M
Cancer Lett; 2022 Jan; 524():161-171. PubMed ID: 34687791
[TBL] [Abstract][Full Text] [Related]
8. Regorafenib inhibits tumor progression through suppression of ERK/NF-κB activation in hepatocellular carcinoma bearing mice.
Weng MC; Wang MH; Tsai JJ; Kuo YC; Liu YC; Hsu FT; Wang HE
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29535278
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
[TBL] [Abstract][Full Text] [Related]
10. Proteoglycan-4 is correlated with longer survival in HCC patients and enhances sorafenib and regorafenib effectiveness via CD44 in vitro.
Dituri F; Scialpi R; Schmidt TA; Frusciante M; Mancarella S; Lupo LG; Villa E; Giannelli G
Cell Death Dis; 2020 Nov; 11(11):984. PubMed ID: 33199679
[TBL] [Abstract][Full Text] [Related]
11. Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.
D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1237-1245. PubMed ID: 25907508
[TBL] [Abstract][Full Text] [Related]
12. The distinct responsiveness of cytokeratin 19-positive hepatocellular carcinoma to regorafenib.
Zhuo J; Lu D; Lin Z; Yang X; Yang M; Wang J; Tao Y; Wen X; Li H; Lian Z; Cen B; Dong S; Wei X; Xie H; Zheng S; Shen Y; Xu X
Cell Death Dis; 2021 Nov; 12(12):1084. PubMed ID: 34785656
[TBL] [Abstract][Full Text] [Related]
13. Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF/VEGFR2 signaling pathways.
El-Hanboshy SM; Helmy MW; Abd-Alhaseeb MM
Mol Biol Rep; 2021 Nov; 48(11):7233-7242. PubMed ID: 34596810
[TBL] [Abstract][Full Text] [Related]
14. Regorafenib inhibits migration, invasion, and vasculogenic mimicry of hepatocellular carcinoma via targeting ID1-mediated EMT.
Zhang N; Zhang S; Wu W; Lu W; Jiang M; Zheng N; Huang J; Wang L; Liu H; Zheng M; Wang J
Mol Carcinog; 2021 Feb; 60(2):151-163. PubMed ID: 33428809
[TBL] [Abstract][Full Text] [Related]
15. miR-590-5p suppresses hepatocellular carcinoma chemoresistance by targeting YAP1 expression.
Chen M; Wu L; Tu J; Zhao Z; Fan X; Mao J; Weng Q; Wu X; Huang L; Xu M; Ji J
EBioMedicine; 2018 Sep; 35():142-154. PubMed ID: 30111512
[TBL] [Abstract][Full Text] [Related]
16. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
Shigeta K; Matsui A; Kikuchi H; Klein S; Mamessier E; Chen IX; Aoki S; Kitahara S; Inoue K; Shigeta A; Hato T; Ramjiawan RR; Staiculescu D; Zopf D; Fiebig L; Hobbs GS; Quaas A; Dima S; Popescu I; Huang P; Munn LL; Cobbold M; Goyal L; Zhu AX; Jain RK; Duda DG
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33234602
[TBL] [Abstract][Full Text] [Related]
17. Collagen I-DDR1 signaling promotes hepatocellular carcinoma cell stemness via Hippo signaling repression.
Xiong YX; Zhang XC; Zhu JH; Zhang YX; Pan YL; Wu Y; Zhao JP; Liu JJ; Lu YX; Liang HF; Zhang ZG; Zhang WG
Cell Death Differ; 2023 Jul; 30(7):1648-1665. PubMed ID: 37117273
[TBL] [Abstract][Full Text] [Related]
18. Role of cellular, molecular and tumor microenvironment in hepatocellular carcinoma: Possible targets and future directions in the regorafenib era.
Juengpanich S; Topatana W; Lu C; Staiculescu D; Li S; Cao J; Lin J; Hu J; Chen M; Chen J; Cai X
Int J Cancer; 2020 Oct; 147(7):1778-1792. PubMed ID: 32162677
[TBL] [Abstract][Full Text] [Related]
19. STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma.
Tai WT; Chu PY; Shiau CW; Chen YL; Li YS; Hung MH; Chen LJ; Chen PL; Su JC; Lin PY; Yu HC; Chen KF
Clin Cancer Res; 2014 Nov; 20(22):5768-76. PubMed ID: 25248379
[TBL] [Abstract][Full Text] [Related]
20. Autophagy-Related Chemoprotection against Sorafenib in Human Hepatocarcinoma: Role of FOXO3 Upregulation and Modulation by Regorafenib.
Fondevila F; Méndez-Blanco C; Fernández-Palanca P; Payo-Serafín T; van Pelt J; Verslype C; González-Gallego J; Mauriz JL
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
